Zentalis Gears Up for Phase 3 Study of Azenosertib after Positive Phase 1b Outcomes

Vandana Singh
1 min read
0
In this article:

  • Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) announced data from the Phase 1b trial of azenosertib in combination with chemotherapy in patients with platinum-resistant ovarian cancer.

  • Azenosertib was well tolerated in combination with multiple types of chemotherapy and demonstrated encouraging clinical activity, with noteworthy improvements in objective response rates (ORRs) and median progression-free survival (mPFS) in all patients, especially those with Cyclin E1+ tumors.

  • 115 patients were enrolled in the study across all chemotherapy combination groups. At the data cut-off of April 10, 2023, 94 were efficacy evaluable.

  • Across all dosing schedules, azenosertib plus paclitaxel demonstrated the highest ORR of 50.0% (mPFS of 7.4m), followed by an ORR of 38.5% (mPFS of 8.3m) for azenosertib plus gemcitabine.

  • Azenosertib plus carboplatin demonstrated an ORR of 35.7% (mPFS of 10.4m), and azenosertib plus PLD demonstrated an ORR of 19.4% (mPFS of 6.3m).

  • The company plans to initiate a Phase 3 study comparing azenosertib dosed intermittently with either carboplatin or paclitaxel in patients with Cyclin E1+ platinum-sensitive ovarian cancer.

  • The company expects to initiate the Phase 3 study in Q1 of 2024.

  • Price Action: ZNTL shares are trading 1.25% higher at $27.50 during premarket trading on the last check Friday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Zentalis Gears Up for Phase 3 Study of Azenosertib after Positive Phase 1b Outcomes originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories